Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 148, Issue 4, Pages 961-970Publisher
WILEY
DOI: 10.1002/ijc.33243
Keywords
brain metastases; breast cancer; overall survival; SRS; surgical resection; systemic therapy; time to progression; whole brain radiotherapy
Categories
Funding
- Sheila Wynne Research Fund
Ask authors/readers for more resources
For patients with breast cancer brain metastasis, whole brain radiotherapy extended overall survival; stereotactic radiosurgery or surgery + stereotactic radiosurgery had equivalent effects on overall survival and local control; Continued chemotherapy including anti-HER2 therapy improved overall survival and time to progression in the brain.
Outcomes of treatments for patients with breast cancer brain metastasis (BCBM) remain suboptimal, especially for systemic therapy. To evaluate the effectiveness of systemic and local therapy (surgery [S], stereotactic radiosurgery [SRS] and whole brain radiotherapy [WBRT]) in BCBM patients, we analyzed the data of 873 BCBM patients from 1999 to 2012. The median overall survival (OS) and time to progression in the brain (TTP-b) after diagnosis of brain metastases (BM) were 9.1 and 7.1 months, respectively. WBRT prolonged OS in patients with multiple BM (hazard ratio [HR], 0.68; 95% CI, 0.52-0.88;P= .004). SRS alone, and surgery or SRS followed by WBRT (S/SRS + WBRT), were equivalent in OS and TTP-b (median OS, 14.9 vs 17.2 months; median TTP-b, 8.2 vs 8.6 months). Continued chemotherapy prolonged OS (HR, 0.35; 95% CI, 0.30-0.41;P< .001) and TTP-b (HR, 0.48; 95% CI, 0.33-0.70;P< .001), however, with no advantage of capecitabine over other chemotherapy agents used (median OS, 11.8 vs 12.4 months; median TTP-b, 7.2 vs 7.4 months). Patients receiving trastuzumab at diagnosis of BM, continuation of anti-HER2 therapy increased OS (HR, 0.53; 95% CI, 0.34-0.83;P= .005) and TTP-b (HR, 0.41; 95% CI, 0.23-0.74;P= .003); no additional benefit was seen with switching over between trastuzumab and lapatinib (median OS, 18.4 vs 22.7 months; median TTP-b: 7.4 vs 8.7 months). In conclusion, SRS or S/SRS + WBRT were equivalent for patients' OS and local control. Continuation systemic chemotherapy including anti-HER2 therapy improved OS and TTP-b with no demonstrable advantage of capecitabine and lapatinib over other agents of physicians' choice was observed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available